CNS Pharmaceuticals, Inc. completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin. CNS' licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement with HPI, the Company acquired multiple U.S. patents for Berubicin. CNS intends to apply for orphan drug status for Berubicin with the FDA for the treatment of malignant glioma.